Table 1.
Included studies: DOI, first author, year of publication, patient population, sample size, age, sex and BMI from the 15 included papers. Abbreviations: NAFLD (nonalcoholic fatty liver disease), ALD (alcohol associated liver disease), NASH (nonalcoholic steatohepatitis). “A” and “B” are different groups that were compared in each study.
| Study Number | Author | Year | Patient Population | Sample Size | Age (Year) | Sex (Fem/Male) | BMI | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | A | B | A | B | A | B | A | B | |||
| 1 | Cabré N | 2022 | Obese NASH (NAS ≥ 5) | Obese non-NASH (NAS ≤ 2) | 8 | 8 | Matched but not specified for this subgroup | Matched but not specified for this subgroup | Matched but not specified for this subgroup | |||
| 2 | Johnson ND | 2021 | G3 = grade 3 fib G3–4 = grade 3–4 fib G4 = grade 4 fib |
G0 = no fibrosis | G3 n = 55 G3–4 n = 36 G4 n = 28 |
206 | G3 49.5 ± 10.0 G3/4 50.4 ± 8.1 G4 53.8 ± 9.5 |
(All 48.6 ± 11.5) G0 47.2 ± 12.4 |
G3 61.8% G3/4 80.5% G4 78.5% |
(All 77%) G0 80.5% |
G3 48.6 ± 8.0 G3/4 46.5 ± 9.7 G4 48.1 ± 12.1 |
All 47.1 ± 9.1 G0 46.6 ± 8.8 |
| 3 | Argemi J | 2019 | AH | Normal liver | 6 | 5 | - | - | - | |||
| 4 | Ulukan B | 2019 | NASH | NAFLD F0 | Cirrhotic NASH (f4) n = 22 (F1/F2 F3) n = 24 |
9 | - | - | - | |||
| 5 | Gerhard GS | 2018 | NAFLD cirrhosis | Normal liver | 11 | 15 | 47.1 ± 6.3 | 51.3 ± 8.2 | 100% women | 41.0 ± 4.6 | 44.4 ± 6.6 | |
| 6 | Lee YR | 2018 | NAFLD | Normal liver | 54 | 18 | - | - | - | |||
| 7 | de Mello V | 2017 | Obese NASH | Obese Normal liver Obese SS |
26 | Normal n = 35 SS n = 34 |
NASH = 51.3 ± 7.9 | Nl = 50.7 ± 7.0 SS = 46.9 ± 7.6 |
13/13 | Nl (11/24) SS (10/24) |
NASH 43.4 ± 6.4 | Nl 42.4 ± 6.1 SS 43.5 ± 4.7 |
| 8 | Nishida N | 2016 | NAFLD | HCC or normal liver | 65 | 16 | 54.3 (50.7–57.9) | 40/25 | - | - | 29.3 (28.0–30.6) | |
| 9 | Kitamoto T | 2015 | advanced fibrosis (F2–4) | Mild fibrosis (F0–1) | 29 | 36 | - | - | - | |||
| 10a | Zeybel M | 2015 | advanced fibrosis (F2–4) | NAFLD, minimal fibrosis | 9 | 8 | 51.88 (40.43–63.32) | 60.56 (54.5–66.61) | 100% male | 35 (30–43.2) | 36 (30–46) | |
| 10b | Zeybel M | 2015 | ALD | Normal liver | 10 | 17 | 63.31 (67.94–54.71) | 46.3 (39.09–57.27) | 10 male (58%) | 7 male (70%) | 24.2 (19–32.5) | |
| 11 | Hui Liu | 2014 | NASH | Alcoholic hepatitis Normal liver |
AH 3–5 NASH 3–5 |
3 | - | - | - | |||
| 12 | Pirola CJ | 2013 | NAFLD (simple steatosis and NASH) | Near normal histology | 22 | Non-MS almost nl n = 18 Steatosis n = 23 |
NASH 48 ± 9.2 |
Nl 48.3 ± 8.7 Stea 51.6 ± 10.5 |
NASH 12/10 |
Fem/male Nl 10/8 Steat 14/9 |
NASH 31.2 ± 6 |
Nl 25.3 ± 4.1 Steat 31.6 ± 5 |
| 13 | Ahrens | 2013 | NASH | No adv Normal control “Healthy” obese Steatosis |
15 | Obese healthy n = 18 Steat n = 12 Normal control n = 18 |
44 (41–50) | 46 (37–49) 47 (40–50) 51 (44–72) |
Male % 0 |
Male % 42 27 50 |
45 (42–49) | 50 (47–55) 49 (44–56) 24 (21–26) |
| 14 | Murphy SK | 2013 | Advanced NAFLD F3–F4 | Mild NAFDL F0–F1 | 23 | 33 | Advanced 51.7 ± 10.3 |
Mild = 51.5 ± 10.3 | Advanced 5/18 |
Mild 12/21 |
Advanced 33.8 (31.3–41.9) |
Mild 32.8 (28.4– 40.4) |
| 15 | Sookoian S | 2010 | NAFLD | NAFLD Control (no histological fatty changes) |
63 | 11 | NAFLD 50.3 ± 9.9 |
49.46 ± 10.2 | NAFLD 32/31 |
Control 5/6 |
NAFLD 31.9 ± 5.6 |
Control 27.9 ± 5.9 |
For the complete list of all extracted data, see also Supplementary Table S1.